EUVIMEDEUVIMED entdecken
Crossref

Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations

Tae Hata, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki und 11 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.07.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Tae Hata und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Pulmonary…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The aim of this study was to identify poor prognostic factors and explore optimal second-line treatment strategies for patients with epidermal growth factor receptor (EGFR)-mutant nonsmall cell lung cancer (NSCLC) who developed resistance to EGFR tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: We retrospectively evaluated patients with advanced or recurrent EGFR-mutant NSCLC who received platinum-based systemic therapy after EGFR-TKI failure from January 2017 to July 2022 at 20 institutions. Logistic regression analysis was used to identify factors associated with 1-year mortality after the start of systemic therapy. RESULTS: We included 393 patients in the final analysis (101 received atezolizumab, bevacizumab, carboplatin, and paclitaxel [ABCP], 292 received chemotherapy); 143 (36.3%) had an overall survival (OS)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedErbB ReceptorsMutationAgedPrognosisSurvival RateCarboplatinDrug Resistance, NeoplasmAdultFollow-Up StudiesPlatinumPaclitaxelAged, 80 and over

Stichwörter der Autor:innen

Bone metastasesEpidermal growth factor receptorImmune checkpoint inhibitorsOverall survivalPrognosis

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsCarboplatinPlatinumPaclitaxel

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Pulmonary Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Electronic address: tayamada@koto.kpu-m.ac.jp.
  • Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
  • Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
  • Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.

Zitieren

APA

Hata, T., Yamada, T., Furuya, N., Tanaka, H., Yoshimura, A., Oba, T., Hibino, M., Fukuda, T., Goto, Y., Nakao, A., Ogusu, S., Okazaki, Y., Harada, T., Ota, T., Masubuchi, K., Mikami, K., Matsumoto, S., Honda, R., Date, K., …, & Takayama, K. (2025). Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.07.014

Vancouver

Hata T, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, et al. Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.07.014

BibTeX
@article{Hata2025,
  author = {Hata, Tae and Yamada, Tadaaki and Furuya, Naoki and Tanaka, Hisashi and Yoshimura, Akihiro and Oba, Tomohiro and Hibino, Makoto and Fukuda, Takahito and Goto, Yasuhiro and Nakao, Akira and Ogusu, Shinsuke and Okazaki, Yuta and Harada, Taishi and Ota, Takayo and Masubuchi, Ken and Mikami, Koji and Matsumoto, Shoki and Honda, Ryoichi and Date, Koji and Chihara, Yusuke and Kawachi, Hayato and Morimoto, Kenji and Takayama, Koichi},
  title = {Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.07.014}
}
Kostenlos starten →